Adn-388

| Species | Dose (mg/kg) | Cmax (µg/mL) | t½ (h) | AUC₀‑∞ (µg·h/mL) | Oral Bioavailability | |---------|--------------|--------------|--------|------------------|----------------------| | Rat | 10 | 4.8 | 6.2 | 38.5 | 84% | | Dog | 5 | 3.2 | 7.4 | 31.1 | 78% | | Non‑human primate (cynomolgus) | 3 | 2.6 | 9.0 | 27.8 | 81% |

ADN‑388 exhibits linear PK across the dose range, minimal food effect, and low plasma protein binding (≈12%). Metabolism is primarily via CYP3A4, generating a single inactive N‑oxide metabolite that is rapidly cleared renally.

ADN-388 follows the dramatic arc typical of the “Husband’s Boss” subgenre. The story centers on Misaki (played by the lead actress), a devoted wife whose husband faces intense pressure from his overbearing and unscrupulous boss. The boss discovers a weakness in the couple—usually financial or career-related—and leverages it to force Misaki into sexual compliance. The narrative explores her slow, psychological breakdown as she moves from vehement refusal to numb acceptance, and finally to conflicted complicity.

ADN-388 is a promising targeted kinase inhibitor with preclinical and early clinical evidence of on-target pharmacology and activity in biomarker-selected tumors. Its future depends on validating predictive biomarkers, defining safe and effective dosing, managing on-target toxicities, and demonstrating clear benefit in later-stage trials—potentially as monotherapy in select patients or in rational combinations to overcome resistance. ADN-388

If you want, I can:

Prepared for the Journal of Emerging Infectious Diseases.

It seems like you've entered "ADN-388" and are looking for information about it, but without more context, it's challenging to provide a specific answer. "ADN-388" could refer to a variety of things, such as a product code, a model number, a document reference, or something else entirely. | Species | Dose (mg/kg) | Cmax (µg/mL)

To give you a more accurate and helpful response, could you please provide more context or details about what "ADN-388" refers to? This would help in identifying what you're looking for.

Title: ADN-388 Studio: Attackers (ADN series - Alice no Niwa) Director: Takuan Release Date: 2022

| Agent | Target | Spectrum | Oral Bioavailability | FDA Status | |-------|--------|----------|----------------------|------------| | Remdesivir | RdRp (SARS‑CoV‑2) | Narrow (CoV) | IV only | Approved (IV) | | Molnupiravir | RdRp (error inducer) | Narrow (CoV) | ~70% | Approved (oral) | | ADN‑388 | Conserved RdRp Motif C | Broad (≥15 RNA families) | ~80% | Conditional (COVID‑19) | | Favipiravir | RdRp (competitive) | Moderate (Flavivirus, Influenza) | 60% | Approved (Japan) | | Virus (Strain) | EC₅₀ (nM) | CC₅₀

ADN‑388’s broad spectrum and high barrier to resistance set it apart from existing agents that are largely virus‑specific.

| Virus (Strain) | EC₅₀ (nM) | CC₅₀ (µM) | Selectivity Index | |----------------|-----------|-----------|-------------------| | SARS‑CoV‑2 (Omicron BA.5) | 12 ± 2 | >10,000 | >800 | | Zika (MR‑766) | 18 ± 3 | >10,000 | >560 | | Nipah (Bangladesh) | 9 ± 1 | >10,000 | >1,100 | | Influenza A (H1N1) | 25 ± 4 | >10,000 | >400 | | Dengue‑2 | 22 ± 5 | >10,000 | >450 |

All assays were performed in human lung epithelial (Calu‑3) or primary neuronal cultures, with cytotoxicity assessed via MTT and LDH release.